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Introduction
Infusions with cytokine-activated NK cells obtained from
blood of MHC mismatched donors have shown some
promising results especially in patients with myeloid
leukaemia. There is also indirect evidence that infusions
of NK cells as part of a stem cell transplant result in
lower relapse rates post-transplant when donor and reci-
pient are mismatched for KIR receptors on NK cells.
Methods
Collecting NK cells form donors requires them to undergo
leukapheresis with subsequent removal of CD3+ lympho-
cytes (to prevent GvHD) and expansion and activation of
the NK cell enriched fraction with IL-2. In contrast, the
continuously growing NK cell line NK-92 can be easily
expanded to clinical scale in bioreactors. The broad cyto-
toxicity of NK-92 is due to the lack of most of the KIR
receptors while expressing a range of activating receptors.
Results
We report here results from concluded and ongoing
clinical phase I studies with NK-92 cells in patients
with advanced cancer, that confirm its safety profile.
Anti-tumour responses were seen in patients with some
advanced haematological malignancies and solid
tumours. NK-92 also provides a platform for further
genetical engineering. A variant has been generated that
expresses a high affinity FcgIIIRA receptor that can aug-
ment the treatment efficacy of mAbs that utilise ADCC
to kill target cells. Various investigators are using the
NK-92 cells as a platform to introduce specific tumour
antigen receptors (i.e. CAR) to make them targeted to
specific tumors such as melanoma, myeloma, leukaemia
or brain cancer. Video-lapse studies show that those
CAR engineered NK-92 cells specifically kill tumour
antigen expressing cancer cells and are able to do ‘serial
killing’. The cell expansion process for NK-92 has been
streamlined and made more economical using various
bioreactor designs.
Conclusion
The human clinical grade NK-92 cell line has many
advantages over peripheral blood NK cells as a cell ther-
apy product for cancer patients. Results from phase I
clinical trials confirm its safety profile. This unique cell
line is now tested in phase II studies for efficacy in var-
ious cancers and is also further developed through
genetic engineering to target specific tumours through
CAR. NK-92 are an off the shelf tumour targeted local
and systemic cell treatment.
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